Merrimack Pharmaceuticals Initiates enrollment in a Phase 2 study of MM-093 in patients with rheumatoid arthritis
rheumatoid arthritis, psoriasis or autoimmune uveitis. MM-093 is an investigational compound and has not been approved by the Food and Drug Administration US or any international regulatory agency.discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the development of high performance networks of protein profiling as a basis for improved validation, lead identification and speed in development of new therapies, effective and safe. Merrimack is a privately held company based in Cambridge, Massachusetts. For more information, visit merrimackpharma. Merrimack Pharmaceuticals, Inc.
Pages: 1 [2]